Clinical Trial Update: Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial [Phase 2]

View source ↗

Summary

This Phase II Bayesian adaptive trial investigates a combination therapy for PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma and is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: Ming-Yuan Chen | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING